Findings showed 67% of the omalizumab group achieved the primary endpoint compared with 7% of the placebo group. Treatment with omalizumab, an anti-IgE antibody, significantly increased the amount of ...

SAN DIEGO -- Omalizumab (Xolair) injections outperformed oral immunotherapy (OIT) in increasing tolerance among children with multi-food allergy, largely because many patients couldn't tolerate OIT, ...

Approval is based on data from the NIH-sponsored Phase III OUtMATCH study, which showed a significantly higher proportion of food allergy patients as young as 1 year treated with Xolair could tolerate ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved the ...

A new study finds that the asthma medication Xolair may substantially reduce severe allergic reactions in people who have multiple food allergies and are accidentally exposed to those foods. Data ...

Compared with placebo, omalizumab significantly increased the amount of peanut, milk, egg, and cashew participants could consume without an allergic reaction. The Food and Drug Administration (FDA) ...

Please provide your email address to receive an email when new articles are posted on . Mean serum total IgE levels began at 2,158 kU/L before increasing to 3,237 kU/L at 1 year and falling to 2,313 ...

A new drug could let those with severe food allergies breathe a sigh of relief. Xolair, or omalizumab, was granted priority review by the Food and Drug Administration on Tuesday for its use in ...

The US Food and Drug Administration (FDA) has approved omalizumab injection (Xolair, Genentech) for children aged 1 year or older and adults to reduce immunoglobulin E─mediated severe allergy to ...

Participants in the OUtMATCH trial are allergic to peanuts and at least two other foods among milk, eggs, wheat, cashews, walnuts and hazelnuts. A clinical trial has found that the medication ...

Xolair is a prescription biologic medicine that is given as an injection under the skin (subcutaneous). It is the only FDA-approved antibody designed to target and block IgE — an underlying driver of ...